[Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract].
Ofloxacine (Tarivid-Hoechst) was used in 30 patients with infections of the respiratory system, including 12 with pneumonias, 18 with chronic bronchitis. The agent was given in oral form, in a 200 mg tablet every 12 hours for 7 to 10 days. Therapeutical and tolerance was analyzed being on clinical radiological, biochemical and bacteriological findings. Complete remission was found in 21 patients, in 7 more a significant clinical and radiological improvement was found. Altogether in 93.3% of the treated patients the therapeutical efficacy of the agent was found to be excellent. During treatment side effects were not observed. The results if this study demonstrate a high therapeutical efficacy and safety of the agent.
Chyrek-Borowska
S
S
Kliniki Alergologii AM, Białymstoku.
Siergiejko
Z
Z
Jakubicz
P
P
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology; D002908:Chronic Disease; D004352:Drug Resistance, Microbial; D013293:Enterococcus faecalis / Q000187:drug effects*; D004926:Escherichia coli / Q000187:drug effects*; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology
D015242:Ofloxacin
Ocena skuteczności ofloksacyny w leczeniu zakazeń układu oddechowego.